233 related articles for article (PubMed ID: 16990649)
41. Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma.
Berger F; Unterholzner S; Diebold J; Knesewitsch P; Hahn K; Spitzweg C
Biochem Biophys Res Commun; 2006 Nov; 349(4):1258-63. PubMed ID: 16982034
[TBL] [Abstract][Full Text] [Related]
42. Regulation of the sodium/iodide symporter by retinoids--a review.
Schmutzler C
Exp Clin Endocrinol Diabetes; 2001; 109(1):41-4. PubMed ID: 11573138
[TBL] [Abstract][Full Text] [Related]
43. A Carboxy-Terminal Monoleucine-Based Motif Participates in the Basolateral Targeting of the Na+/I- Symporter.
Martín M; Modenutti CP; Peyret V; Geysels RC; Darrouzet E; Pourcher T; Masini-Repiso AM; Martí MA; Carrasco N; Nicola JP
Endocrinology; 2019 Jan; 160(1):156-168. PubMed ID: 30496374
[TBL] [Abstract][Full Text] [Related]
44. The Na+/I- symporter (NIS): mechanism and medical impact.
Portulano C; Paroder-Belenitsky M; Carrasco N
Endocr Rev; 2014 Feb; 35(1):106-49. PubMed ID: 24311738
[TBL] [Abstract][Full Text] [Related]
45. [Sodium iodide symporter in physiology and diseases -- the current state of knowledge].
Wolny M; Syrenicz A
Endokrynol Pol; 2007; 58(6):512-21. PubMed ID: 18205108
[TBL] [Abstract][Full Text] [Related]
46. Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.
Fletcher A; Read ML; Thornton CEM; Larner DP; Poole VL; Brookes K; Nieto HR; Alshahrani M; Thompson RJ; Lavery GG; Landa I; Fagin JA; Campbell MJ; Boelaert K; Turnell AS; Smith VE; McCabe CJ
Cancer Res; 2020 Jan; 80(1):102-115. PubMed ID: 31672844
[TBL] [Abstract][Full Text] [Related]
47. Different expression of sodium-iodide importer (NIS) between lactating breast and thyroid tissues may be due to structural difference of thyroid-stimulating hormone receptor (TSHR).
Shi XZ; Xue L; Jin X; Xu P; Jia S; Shen HM
J Endocrinol Invest; 2017 Jan; 40(1):41-48. PubMed ID: 27531173
[TBL] [Abstract][Full Text] [Related]
48. The sodium-iodide symporter.
Baker CH; Morris JC
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):167-74. PubMed ID: 15379719
[TBL] [Abstract][Full Text] [Related]
49. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections.
Wapnir IL; van de Rijn M; Nowels K; Amenta PS; Walton K; Montgomery K; Greco RS; Dohán O; Carrasco N
J Clin Endocrinol Metab; 2003 Apr; 88(4):1880-8. PubMed ID: 12679487
[TBL] [Abstract][Full Text] [Related]
51. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.
Saito T; Endo T; Kawaguchi A; Ikeda M; Katoh R; Kawaoi A; Muramatsu A; Onaya T
J Clin Invest; 1998 Apr; 101(7):1296-300. PubMed ID: 9525971
[TBL] [Abstract][Full Text] [Related]
52. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
53. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
Peyrottes I; Navarro V; Ondo-Mendez A; Marcellin D; Bellanger L; Marsault R; Lindenthal S; Ettore F; Darcourt J; Pourcher T
Eur J Endocrinol; 2009 Feb; 160(2):215-25. PubMed ID: 19029227
[TBL] [Abstract][Full Text] [Related]
54. The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells.
Heltemes LM; Hagan CR; Mitrofanova EE; Panchal RG; Guo J; Link CJ
Cancer Gene Ther; 2003 Jan; 10(1):14-22. PubMed ID: 12489024
[TBL] [Abstract][Full Text] [Related]
55. [The sodium-iodide-symporter (NIS): function, regulation and clinical importance].
Köhrle J
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():17-22. PubMed ID: 10355044
[TBL] [Abstract][Full Text] [Related]
56. Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer.
Riedel C; Dohán O; De la Vieja A; Ginter CS; Carrasco N
Trends Biochem Sci; 2001 Aug; 26(8):490-6. PubMed ID: 11504625
[TBL] [Abstract][Full Text] [Related]
57. Stimulation of retinoic acid-induced functional sodium iodide symporter (NIS) expression and cytotoxicity of ¹³¹I by carbamazepine in breast cancer cells.
Willhauck MJ; O Kane DJ; Wunderlich N; Göke B; Spitzweg C
Breast Cancer Res Treat; 2011 Jan; 125(2):377-86. PubMed ID: 20300827
[TBL] [Abstract][Full Text] [Related]
58. Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach.
Riesco-Eizaguirre G; De la Vieja A; Rodríguez I; Miranda S; Martín-Duque P; Vassaux G; Santisteban P
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1435-43. PubMed ID: 21697253
[TBL] [Abstract][Full Text] [Related]
59. Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells.
Lundh C; Lindencrona U; Postgård P; Carlsson T; Nilsson M; Forssell-Aronsson E
J Nucl Med; 2009 Jul; 50(7):1161-7. PubMed ID: 19525464
[TBL] [Abstract][Full Text] [Related]
60. The Na/I symporter (NIS): imaging and therapeutic applications.
Dadachova E; Carrasco N
Semin Nucl Med; 2004 Jan; 34(1):23-31. PubMed ID: 14735456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
